Skip to content

Clinical Pharmacology & Therapeutics

ISSN 0009-9236, 1532-6535

43 papers in the library · 2,241 citations · publishing 1964-2026

Papers

Sort Most recent Most cited

Microdosing of a Carbon-14 Labeled Protein in Healthy Volunteers Accurately Predicts Its Pharmacokinetics at Therapeutic Dosages.

Clinical Pharmacology & Therapeutics August 2015 Maria L H Vlaming, Esther van Duijn, M R Dillingh et al.

Preclinical development of new biological entities (NBEs), such as human protein therapeutics, requires considerable expenditure of time and costs. Poor prediction of pharmacokinetics in humans further reduces net efficiency. In this study, we show for the first time that pharmacokinetic data of NBEs in humans can be successfully obtained early in the drug development process by the use of...

Cannabis and the maturing brain: Role in psychosis development

Clinical Pharmacology & Therapeutics June 1, 2015 CE Crocker, PG Tibbo

A common viewpoint has proliferated that cannabis use is mostly harmless. Some argue that by not supporting its use, we are missing a great therapeutic opportunity. The general public view on cannabis may partially be a result of poor knowledge translation. In fact, the “war on drugs” approach has not allowed for basic education on the varied effects of cannabis on the brain, especially at...

Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study

Clinical Pharmacology & Therapeutics August 10, 2011 Kazuya Maeda, Yasumasa Ikeda, Tomoe Fujita et al. 207 citations

Clearance of atorvastatin occurs through hepatic uptake by organic anion transporting polypeptides (OATPs) and subsequent metabolism by cytochrome P450 (CYP) 3A4. To demonstrate the relative importance of OATPs and CYP3A4 in the hepatic elimination of atorvastatin in vivo, a clinical cassette microdose study was performed. A cocktail consisting of a microdose of atorvastatin along with probe...

DOI: 10.1038/clpt.2011.142 (opens in new tab) Atorvastatin Pharmacology Microdose Cyp3a4 +10

Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.

Clinical Pharmacology & Therapeutics August 2011 Marko A. Peltoniemi, Teijo I. Saari, Nora M. Hagelberg et al.

This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at...

A Perhaps Unexpected Role of Norepinephrine in Actions of MDMA

Clinical Pharmacology & Therapeutics July 20, 2011 Thomas F. Newton 9 citations

In this issue, Hysek and colleagues present new data describing the impact of treatment with reboxetine on the effects produced by 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in human volunteers. They demonstrate that several effects of MDMA are mediated by reboxetine's actions on norepinephrine (NE) transporters, an unexpected finding. Building on earlier work, their new data provide...

Nonlinear Pharmacokinetics of Oral Quinidine and Verapamil in Healthy Subjects: A Clinical Microdosing Study

Clinical Pharmacology & Therapeutics June 29, 2011 Kazuya Maeda, Junichi Takano, Yasumasa Ikeda et al. 50 citations

Microdosing studies are effective in enabling the early identification of the pharmacokinetic properties of compounds administered to humans. However, the nonlinearity of the pharmacokinetics between microdose and therapeutic dose, attributable to the saturation of metabolic enzymes and transporters, is a major concern. Verapamil and quinidine are good substrates of both the multidrug...

DOI: 10.1038/clpt.2011.108 (opens in new tab) Quinidine Verapamil Pharmacokinetics Clinical pharmacology

The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (“Ecstasy”) in Humans

Clinical Pharmacology & Therapeutics June 15, 2011 Cédric M. Hysek, Linda D. Simmler, M. Ineichen et al. 153 citations

This study assessed the pharmacodynamic and pharmacokinetic effects of the interaction between the selective norepinephrine (NE) transporter inhibitor reboxetine and 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in 16 healthy subjects. The study used a double-blind, placebo-controlled crossover design. Reboxetine reduced the effects of MDMA including elevations in plasma levels of NE,...

Subjective and physiological effects after controlled Sativex and oral THC administration.

Clinical Pharmacology & Therapeutics March 2011 E L Karschner, William D Darwin, Robert P McMahon et al.

Sativex is a cannabis-plant extract delivering nearly 1:1 Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) by oromucosal spray. It has been suggested that CBD attenuates THC-induced tachycardia, anxiety, and euphoria. In this study, pharmacodynamic effects were compared over 10.5 h in nine cannabis smokers randomly assigned to receive placebo, 5 and 15 mg oral synthetic THC, and low (5.4...

Innovative Early Development Regulatory Approaches: expIND, expCTA, Microdosing

Clinical Pharmacology & Therapeutics December 19, 2007 WT Robinson 37 citations

The Food and Drug Administration (FDA) Critical Path Initiative as well as the European Medicines Agency Road Map to 2010 (ref. 2) call for opportunities for more efficient drug development. One of the initiatives that has emerged in this context is the elaboration through guidance of exploratory investigational new drugs (INDs)/clinical trial applications (CTAs). This article reviews the...

Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs

Clinical Pharmacology & Therapeutics September 1, 2006 Graham Lappin, W. Kuhnz, R. Jochemsen et al. 242 citations

OBJECTIVES: A volunteer trial was performed to compare the pharmacokinetics of 5 drugs--warfarin, ZK253 (Schering), diazepam, midazolam, and erythromycin--when administered at a microdose or pharmacologic dose. Each compound was chosen to represent a situation in which prediction of pharmacokinetics from either animal or in vitro studies (or both) was or is likely to be problematic. METHODS: In...

DOI: 10.1016/j.clpt.2006.05.008 (opens in new tab) Microdose Pharmacokinetics Pharmacology Therapeutic index +6

Stereoselective pharmacokinetics of ketamine: R(−)‐Ketamine inhibits the elimination of S(+)‐ketamine

Clinical Pharmacology & Therapeutics November 1, 2001 Harald Ihmsen, Gerd Geisslinger, Jürgen Schüttler

ObjectiveWe investigated the pharmacokinetics of ketamine with special regard to enantiomer‐specific differences.MethodsTen healthy young male volunteers (mean age, 28 ± 4 years; mean weight, 79 ± 11 kg) received racemic ketamine and S(+)‐ketamine in a randomized double‐blind crossover study. Drugs were administered by a computer‐controlled device. Two infusion cycles with linearly increasing...

Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers.

Clinical Pharmacology & Therapeutics August 1, 1995 P Hartvig, J Valtysson, K J Lindner et al.

Plasma concentrations, maximum regional brain concentrations, and specific regional binding in the brain after administration of 0, 0.1, and 0.2 mg/kg doses of (S)-ketamine were measured in a randomized, double-blind, crossover study in five volunteers and were related to induced effects such as analgesia, amnesia, and mood changes. Specific binding in the brain was assessed by simultaneous...

Characterization of the absorption phase of marijuana smoking.

Clinical Pharmacology & Therapeutics July 1992 Marilyn A. Huestis, A H Sampson, B J Holicky et al.

Rapid blood collection, a paced smoking protocol and timely collection of physiologic and behavioral measures were used to characterize the absorption phase of marijuana smoking. Six healthy males smoked a single marijuana cigarette (placebo, 1.75%, or 3.55% delta-9-tetrahydrocannabinol) in a double-blind, randomized, Latin square study design. Rapid blood sampling with a continuous withdrawal...

Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol.

Clinical Pharmacology & Therapeutics July 1975 L E Hollister, H Gillespie

Oral doses of delta-9-tetrahydrocannabinol (THC) 20 mg, combined with placebo or with 40 mg dses of cannabinol (CBN) and cannabidiol (CBD), were given to volunteers. The combination of THC with CBN produced no detectable changes in the quality, intensity, or duration of the effects of THC alone. The THC-CBD combination tended to delay onset and prolong effects of THC, while making them somewhat...

Comparison of tetrahydrocannabinol and synhexyl in man

Clinical Pharmacology & Therapeutics November 1, 1968 Leo E. Hollister, R. K. Richards, H. K. Gillespie 195 citations

A synthetic isomer of tetrahydrocannabinol (1‐Δ'‐3,4‐transtetrahydrocannabinol), believed to be identical to the most active naturally occurring THC, was compared with a semisynthetic THC‐like compound, synhexyl. Sixteen volunteer subiects received THC in doses ranging from 341 to 946 p.g per kilo gram (median 581). Thirteen subjects received synhexyl in doses ranging from 633 to 2,666 µg per...

Correlation of performance test scores with “tissue concentration” of lysergic acid diethylamide in human subiects

Clinical Pharmacology & Therapeutics September 1, 1968 John G. Wagner, George K. Aghajanian, O. Bing 61 citations

Previously published plasma concentrations of LSD‐25, observed following intravenous iniection of 2 mcg. per kilogram of LSD‐25, have been found to be explained by the two‐compartment open model. Performance scores on arithmetic tests were shown to be highly linearly correlated with the concentration in the “tissue” (outer) compartment. The estimated volume of the plasma (inner) compartment was...

DOI: 10.1002/cpt196895635 (opens in new tab) Lysergic acid diethylamide Compartment ship Body weight Extracellular fluid +3

D‐Lysergic acid diethylamide (LSD): A review of its present status

Clinical Pharmacology & Therapeutics March 1, 1965 A. Hoffer 83 citations

This is a review of an important but controversial subject, written by one of the important figures involved in the controversy. It was not possible to get a review in depth by someone who was not also involved in the controversy. With this in mind, this review was accepted for publication because it was written by an authority actively engaged in the problem and because it was thought...

DOI: 10.1002/cpt196562183 (opens in new tab) Lysergic acid diethylamide Subject documents Audience measurement Law +1

Persistence of lysergic acid diethylamide in the plasma of human subjects

Clinical Pharmacology & Therapeutics September 1, 1964 George K. Aghajanian, O. Bing 118 citations

Two micrograms per kilogram of LSD‐25 was administered intravenously to five normal human subjects. The concentration of drug in plasma was determined serially over the subsequent 8 hours. LSD‐25 was found to be present in human plasma in relatively large quantities during the period of peak effect. The half‐life of LSD‐25 in human plasma was calculated to be 175 minutes.

DOI: 10.1002/cpt196455611 (opens in new tab) Lysergic acid diethylamide Human plasma Persistence discontinuity Plasma levels +5